First Heartland Consultants’s VanEck Biotech ETF BBH Stock Holding History

First Heartland Consultants’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,265	Closed	-$215K	–	388
2020 Q4	$215K	Hold	1,265	–	–	0.04%	314
2020 Q3	$205K	Buy	+1,265	New	+$206K	0.04%	276

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

First Heartland Consultants's BBH Position: Q1 2021 in Review

First Heartland Consultants sold out of VanEck Biotech ETF (BBH) in Q1 2021, closing a stake of 1,265 shares — an estimated $215K sold.

First Heartland Consultants first reported a position in BBH in Q3 2020 and held it in 2 quarters. The position peaked at $215K in Q4 2020. 105 funds tracked by Wall St. Rank hold BBH as of Q1 2021.

First Heartland Consultants reported no remaining VanEck Biotech ETF position as of Q1 2021 after selling out during the quarter.
First Heartland Consultants sold 1,265 VanEck Biotech ETF shares in Q1 2021, an estimated $215K.
First Heartland Consultants first reported a position in VanEck Biotech ETF in Q3 2020 and held it in 2 quarters.
First Heartland Consultants's VanEck Biotech ETF position peaked at $215K in Q4 2020.
105 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2021.

Based on First Heartland Consultants's 13F filing for Q1 2021, filed 17 May 2021.